AU628913B2 - Pyrazolopyridine compound and processes for preparation thereof - Google Patents

Pyrazolopyridine compound and processes for preparation thereof Download PDF

Info

Publication number
AU628913B2
AU628913B2 AU48696/90A AU4869690A AU628913B2 AU 628913 B2 AU628913 B2 AU 628913B2 AU 48696/90 A AU48696/90 A AU 48696/90A AU 4869690 A AU4869690 A AU 4869690A AU 628913 B2 AU628913 B2 AU 628913B2
Authority
AU
Australia
Prior art keywords
compound
salt
formula
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48696/90A
Other languages
English (en)
Other versions
AU4869690A (en
Inventor
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Youichi Shiokawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of AU4869690A publication Critical patent/AU4869690A/en
Application granted granted Critical
Publication of AU628913B2 publication Critical patent/AU628913B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU48696/90A 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof Ceased AU628913B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8901423 1989-01-23
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof

Publications (2)

Publication Number Publication Date
AU4869690A AU4869690A (en) 1990-07-26
AU628913B2 true AU628913B2 (en) 1992-09-24

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48696/90A Ceased AU628913B2 (en) 1989-01-23 1990-01-23 Pyrazolopyridine compound and processes for preparation thereof

Country Status (23)

Country Link
US (1) US4985444A (OSRAM)
EP (1) EP0379979B1 (OSRAM)
JP (2) JPH0794454B2 (OSRAM)
KR (1) KR0159502B1 (OSRAM)
CN (1) CN1031570C (OSRAM)
AT (1) ATE150462T1 (OSRAM)
AU (1) AU628913B2 (OSRAM)
CA (1) CA2008263C (OSRAM)
DE (1) DE69030206T2 (OSRAM)
DK (1) DK0379979T3 (OSRAM)
ES (1) ES2098229T3 (OSRAM)
FI (1) FI96205C (OSRAM)
GB (1) GB8901423D0 (OSRAM)
GR (1) GR3023219T3 (OSRAM)
HU (2) HUT53368A (OSRAM)
IE (1) IE900161L (OSRAM)
IL (1) IL93050A (OSRAM)
NO (1) NO176356C (OSRAM)
PH (1) PH30968A (OSRAM)
PT (1) PT92935B (OSRAM)
RU (1) RU2007403C1 (OSRAM)
UA (1) UA43821C2 (OSRAM)
ZA (1) ZA90200B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
JP3269084B2 (ja) * 1992-06-10 2002-03-25 藤沢薬品工業株式会社 貧血治療のためのピラゾロピリジン化合物
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
KR100386542B1 (ko) * 1993-12-29 2003-10-11 후지사와 야꾸힝 고교 가부시키가이샤 피라졸로피리딘아데노신길항제
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
DE69731948D1 (de) * 1996-04-25 2005-01-20 Fujisawa Pharmaceutical Co Mittel zur vorbeugung und heilung ischämischer darmlesion und ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
EP0989129B1 (en) * 1996-10-04 2002-12-11 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
US6303624B1 (en) 1997-03-18 2001-10-16 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
HRP20000122B1 (en) * 1997-09-05 2003-06-30 Glaxo Group Ltd 2,3-diaryl-pyrazolo/1,5-b/pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2)
ATE342734T1 (de) * 1998-06-01 2006-11-15 Astellas Pharma Inc Adenosin a1 antagonisten gegen männliche sterilität
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
BR9915011A (pt) 1998-11-03 2001-08-07 Glaxo Group Ltd Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US7163940B2 (en) * 2000-12-15 2007-01-16 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
ES2245380T3 (es) * 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
ES2316546T3 (es) * 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
DE60201074T2 (de) * 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
EP1372642A1 (en) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
US7141569B2 (en) * 2001-04-10 2006-11-28 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
WO2002088121A1 (en) * 2001-04-27 2002-11-07 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
ES2242028T3 (es) * 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
PL366827A1 (en) * 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
ATE364043T1 (de) * 2001-09-07 2007-06-15 Smithkline Beecham Corp Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
US7244740B2 (en) * 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ES2292839T3 (es) * 2001-12-11 2008-03-16 Smithkline Beecham Corporation Derivados de pirazolo-piridina como agentes contra el herpes.
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7153863B2 (en) * 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
AU2007258567B2 (en) * 2006-06-06 2012-04-19 Medicinova, Inc. Substituted pyrazolo (1,5-alpha) pyridine compounds and their methods of use
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
US8431603B2 (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compounds
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
ES2574253T3 (es) * 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
BR112014026643B1 (pt) 2012-04-26 2023-03-07 Universite De Montreal Derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica
MX2014012741A (es) 2012-04-26 2015-04-13 Bristol Myers Squibb Co Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria.
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
US9499543B2 (en) * 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
JP6051392B1 (ja) * 2014-08-05 2016-12-27 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのセリン誘導体
SG11202109568TA (en) * 2019-03-20 2021-10-28 Goldfinch Bio Inc Pyridazinones and methods of use thereof
KR20220043919A (ko) * 2020-09-29 2022-04-05 연세대학교 산학협력단 호흡기 질환의 예방 또는 치료용 조성물 및 예방 또는 치료 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
LU84860A1 (fr) * 1982-06-16 1984-03-07 May & Baker Ltd Nouveau derive de la pyrazolo(1,5-a)pyridine,sa preparation et les compositions pharmaceutiques qui le contiennent
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594170B2 (en) * 1986-07-08 1990-03-01 Synthelabo Nitrofuran derivatives, their preparation and compositions containing them
AU605518B2 (en) * 1986-11-26 1991-01-17 Japanese Foundation For Cancer Research Promoting agents of the activity of some antitumor agents against various kinds of tumor cells including multiple drug resistant tumor cells and their synthetic methods
AU587931B2 (en) * 1987-04-01 1989-08-31 Boehringer Mannheim Gmbh Chromogenic compounds, processes for the preparation thereof and the use thereof as enzyme substrates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651353B2 (en) * 1990-07-18 1994-07-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
UA43821C2 (uk) 2002-01-15
CA2008263C (en) 2000-03-14
KR900011773A (ko) 1990-08-01
ZA90200B (en) 1990-10-31
HU211684A9 (en) 1995-12-28
FI96205B (fi) 1996-02-15
JPH0794454B2 (ja) 1995-10-11
US4985444A (en) 1991-01-15
DE69030206D1 (de) 1997-04-24
IL93050A0 (en) 1990-11-05
CN1044656A (zh) 1990-08-15
PT92935A (pt) 1990-07-31
ES2098229T3 (es) 1997-05-01
FI96205C (fi) 1996-05-27
NO900306D0 (no) 1990-01-22
PH30968A (en) 1997-12-23
IE900161L (en) 1990-07-23
AU4869690A (en) 1990-07-26
GR3023219T3 (en) 1997-07-30
IL93050A (en) 1995-05-26
PT92935B (pt) 1995-12-29
JPH02243689A (ja) 1990-09-27
EP0379979B1 (en) 1997-03-19
KR0159502B1 (ko) 1998-12-01
DE69030206T2 (de) 1997-07-10
NO176356C (no) 1995-03-22
HUT53368A (en) 1990-10-28
EP0379979A1 (en) 1990-08-01
NO176356B (no) 1994-12-12
NO900306L (no) 1990-07-24
DK0379979T3 (OSRAM) 1997-04-07
CN1031570C (zh) 1996-04-17
GB8901423D0 (en) 1989-03-15
ATE150462T1 (de) 1997-04-15
RU2007403C1 (ru) 1994-02-15
CA2008263A1 (en) 1990-07-23
FI900307A0 (fi) 1990-01-19
HU900228D0 (en) 1990-03-28
JPH0881465A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
AU628913B2 (en) Pyrazolopyridine compound and processes for preparation thereof
US5155114A (en) Method of treatment using pyrazolopyridine compound
AU651353B2 (en) Pyrazolopyridine compound and processes for preparation thereof
EP0370381B1 (en) 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU694157B2 (en) Pyrazolopyridine adenosine antagonists
SK199592A3 (en) Heterocycylic compounds, their manufacture and use
CA1309095C (en) Aminoimidazoquinoline derivatives
EP0636626A1 (en) Pyrazolopyrimidine Derivatives
JPH04346978A (ja) ベンズイミダゾール類及びこれらの化合物を含有する薬剤組成物
US5354759A (en) Angiotenin II antagonizing heterocyclic compounds
MXPA06014699A (es) Derivados de pirazolo-piridina.
WO2004082616A2 (en) Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
JP2004512323A (ja) Ｃｃｒ５ケモカイン受容体活性のピロリジンモジュレーター
AU597190B2 (en) Therapeutic agents
US20090298872A1 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
KR20250023365A (ko) 알파 4 베타 7 인테그린 조정제 및 그의 용도
JPH10513172A (ja) ５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
EP0553682A1 (en) Imidazo 4,5-b pyridine derivatives as Angiotensin II antagonists
KR20060092219A (ko) 유도성 ｎｏ-합성효소 억제제로서의 아미노피리딘-유도체
EP1915373B1 (en) Heterobicyclic compounds useful as p38 kinase inhibiting agents
US5348960A (en) Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
JPS59141580A (ja) インド−ル誘導体
CA2631794A1 (en) P38 kinase inhibiting agents

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired